Freedom of Information request on for Drug Analysis Prints (DAPs) for vaccines on the routine immunisation schedule (FOI 21/1133)
Published 26 May 2022
© Crown copyright 2022
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/freedom-of-information-responses-from-the-mhra-week-commencing-8-november-2021/freedom-of-information-request-on-for-drug-analysis-prints-daps-for-vaccines-on-the-routine-immunisation-schedule-foi-211133
FOI 21/1133
10th November 2021
Dear,
Thank you for your email dated 13th October 2021, where you asked for Drug Analysis Prints (DAPs) for the following vaccines on the routine immunisation schedule:
• DTaP/IPV/Hib/HepB
• Meningitis B
• Rotavirus
• Pneumococcal conjugate vaccine (PCV)
• Hib/MenC
• MMR
• DTaP/IPV
• Live attenuated influenza vaccine (LAIV)
• Human Papilloma Virus (HPV)
• Meningitis A,C,W,Y
• Td/IPV
As per your request, please find attached a DAP for each of the vaccines requested above. Each of the prints contains information on all of the UK spontaneous suspected Adverse Drug Reaction (ADR) reports received through the Yellow Card scheme up to and including 30/09/2021. Please note that these data include reports received for all brands of each vaccine as well as reports in which the brand name was not provided by the reporter. For example, the data in the MMR DAP includes reports relating to all MMR vaccines including Priorix, MMR VaxPRO and reports in which an MMR vaccine was reported but a brand name was not provided. Please also find attached a DAP guidance sheet which provides you with further information on how to interpret the prints.
When considering the attached spontaneous data, it is important to be aware of the following points:
• A reported reaction does not necessarily mean it has been caused by the vaccine, only that the reporter had a suspicion it may have. Each year, millions of doses of routine vaccinations are given in the UK alone, and when any vaccine is administered to large numbers of people, some recipients will inevitably experience illness following vaccination. The fact that symptoms occur after use of a
vaccine or medicine, and are reported via the Yellow Card Scheme, does not in itself mean that they are proven to have been caused by it. Underlying or concurrent illnesses may be responsible and such events can also be coincidental.
• It is also important to note that the number of reports received via the Yellow Card scheme does not directly equate to the number of people who suffer adverse reactions and therefore cannot be used to determine the incidence of a reaction or compare the safety profile of different vaccines. ADR reporting rates are influenced by the seriousness of ADRs, their ease of recognition, the extent of use of a particular vaccine and may be stimulated by promotion and publicity about a particular vaccine. Reporting tends to be highest for newly introduced medicines or vaccines during the first one to two years on the market and then falls over time.
As these data do not necessarily refer to proven side effects, you should refer to the product information which can be found here:MHRA Products Home for details on the possible known side effects of each of the vaccines.
Any emerging evidence relating to possible risks associated with vaccines and medicines, is carefully reviewed and, if appropriate, regulatory action would be taken if any serious risks were confirmed.
I hope the information provided is helpful, but if you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of this response; and can be addressed to this email address.
Yours sincerely,
FOI Team,
Vigilance and Risk Management of Medicines Division
The MHRA information supplied in response to your request is subject to Crown copyright. The FOIA only entitles you to access to MHRA information. For information on the reproduction or re-use of MHRA information, please visit https://www.gov.uk/government/publications/reproduce-or-re-use-mhra-information/reproduce-or-re-use-mhra-information
If you have a query about this email, please contact us. If you are unhappy with our decision, you may ask for it to be reviewed. That review will be undertaken by a senior member of the Agency who has not previously been involved in your request. If you wish to pursue that option please write to the Communications Directorate, 4-T, Medicines and Healthcare products Regulatory Agency, (via this email address). After that, if you remain dissatisfied, you may ask the Information Commissioner at:
The Information Commissioner’s Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF